This site is intended for health professionals only

Published on 4 October 2011

Share this story:

Oral antibiotic launched for travellers’ diarrhoea


Norgine has launched an effective antibiotic for treating non-invasive travellers’ diarrhoea (TD) after a licence was granted for prescription in the UK.

Xifaxanta™ is the first oral antibiotic for the treatment of TD, which remains almost entirely inside the gut (<99%).

As such, the potential for resistance is low, despite Xifaxanta’s use in many countries over several years.

In addition, the risk of systemic side effects and/or drug-drug interactions is reduced.

Xifaxanta™ presents prescribers with an opportunity to treat TD efficiently, but without the concerns of inducing systemic bacterial resistance.

Xifaxanta™ has been available in the USA and other European countries since 2004, but can now be prescribed by UK general practitioners and travel clinics to patients travelling to high-risk destinations as a ‘stand by treatment’.

Administration is via a course of tablets to be taken thrice daily for three days.

The following patients in particular could benefit from taking Xifaxanta™:
Р   Those visiting high-risk regions
Р   Those with increased susceptibility to infection (eg immunocompromised)
Р   Those for whom an episode of TD would adversely disrupt their planned activities
Р   Those returning from travel with uncomplicated TD

A clinical trial found no significant difference between the efficacy of Xifaxanta™ and Ciprofloxacin in non-invasive TD.

The median time from taking XifaxantaTM until the last unformed stool was between 32 and 32½ hours.

Clinical ‘wellness’ was achieved significantly faster with Xifaxanta™-containing regimens compared with Loperamide alone.

Xifaxanta™ was generally well tolerated and associated with a low incidence of adverse events, which were generally mild to moderate in severity.

The most commonly reported events were gastrointestinal in nature, such as flatulence and abdominal pain.

Xifaxanta™ has not been associated with clinically significant cross-resistance to other members of the rifamycin class, in particular Rifampicin.

Travellers’ Diarrhoea

Most read

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: